84126-48-7

Upstream product

• 1145-80-8 N-(benzyloxycarbonyl)-L-serine 
• 74-88-4 methyl iodide 
• 1676-81-9 N-benzyloxycarbonyl-L-serine methyl ester 

Downstream Products

• 323581-36-8 benzyl [(2R)-1-hydroxy-3-methoxypropan-2-yl]carbamate 
• 1429777-62-7 (2S)-2-{[(benzyloxy)carbonyl]amino}-3-methoxypropyl methanesulfonate 
• 1429777-61-6 benzyl [(2R)-1-amino-3-methoxypropan-2-yl]carbamate 
• 1446087-67-7 (S)-benzyl (1-methoxy-3-((trimethylsilyl)oxy)propan-2-yl)carbamate 
• 1446087-70-2 C₂₁H₂₇N₃O₉ 
• 134807-65-1 (S)-2-(((benzyloxy)carbonyl)amino)-3-methoxypropanoic acid 
• 1446087-71-3 5'-O-DMT-2'-O-(N-benzyloxycarbonyl-2'-O-S-AMP)uridine 
• 1446087-69-9 C₂₁H₂₇N₃O₉ 

Relevant academic research and scientific papers

BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS

Compounds of formula (I) and salts thereof: wherein R1, R2, R3, R4 are defined herein. Compounds of formula (I) and salts thereof have been found to inhibit the binding of the BET family of bromodomain proteins to, for example, acetylated lysine residues and thus may have use in therapy, for example in the treatment of autoimmune and inflammatory diseases, such as rheumatoid arthritis; and cancers.

NOVEL 2'/3'/5'-(R/S)-SERINYL FUNCTIONALIZED OLIGONUCLEOTIDES

The present invention provides novel chiral serinyl functionalized tethered oligonucleotides i.e. R/S serinyl functionalized tethered oligonucleotides and the process of preparation thereof. Specifically, the present invention provides a modified nucleosi

3-PYRIDYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS

The invention provides certain 3-pyridyl carboxamide-containing compounds of the Formula (I) (I) or pharmaceutically acceptable salts thereof, wherein A and B are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk) kinase.

Synthesis and properties of 2′-O-[R- and S-(2-amino-3-methoxy)propyl] (R-AMP and S-AMP) nucleic acids

Substitution at 2′-position by either amino- or methoxy-pendant groups of the antisense oligonucleotides (AONs) is known to enhance their therapeutic value. A simple modification is described here in which we introduce both these groups in the form of ena